Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 13/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.50 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518824 | 0.90 | PARP1 (0.58) | TDP1L3MBTL1CES1MAPK14PARP1 | |
| SCHEMBL6954820 | 0.89 | MAPK14 (0.65) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL8251126 | 0.87 | MAPK14 (0.55) | TDP1L3MBTL1MAPK14PARP1PARP10 | |
| SCHEMBL11140087 | 0.86 | MAOA (0.57) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL18533302 | 0.84 | TDP1 (0.46) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL44496 | 0.82 | CES1 (0.90) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL29408351 | 0.82 | CES1 (0.90) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL29437756 | 0.82 | CES1 (0.90) | TDP1L3MBTL1CES1MAPK14MAOA | |
| SCHEMBL6387885 | 0.79 | MAPK14 (0.60) | TDP1L3MBTL1MAPK14PARP1PARP10 | |
| SCHEMBL3372953 | 0.78 | SRD5A1 (0.54) | MAPK14PARP1PARP10SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10476006-B2 | Compound and organic electronic device using the same | SHANGHAI NICHEM FINE CHEMICAL CO., LTD. (CN) | 2019-11-12 | — | — | US | disclosed |
| EP-3281936-B1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | SHANGHAI NICHEM FINE CHEMICAL CO LTD (CN) | 2019-10-09 | — | — | EP | disclosed |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-02-15 | — | — | US | disclosed |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | NICHEM FINE TECHNOLOGY CO., LTD. (TW) | 2018-02-15 | — | — | US | disclosed |
| EP-3281936-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | Nichem Fine Technology Co., Ltd. (TW) | 2018-02-14 | — | — | EP | disclosed |
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1998056752-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| US-4929621-A | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | SYNTHELABO (FR) | 1990-05-29 | — | — | US | disclosed |
| US-4891376-A | MIGRAINE | SYNTHELABO (FR) | 1990-01-02 | — | — | US | disclosed |
| EP-0115690-A1 | Dibenzocycloheptenylidenes | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | TDP1 3931/4885L3MBTL1 4870/4885CES1 439/4885 |
| US-10476006-B2 | Compound and organic electronic device using the same | ESR1, AOC2, PIEZO1 | TDP1 2975/4885L3MBTL1 1194/4885CES1 940/4885 |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | TDP1 682/4885L3MBTL1 656/4885CES1 2100/4885 |
| US-20180047908-A1 | COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME | ESR1, AOC2, PIEZO1 | TDP1 2975/4885L3MBTL1 1194/4885CES1 940/4885 |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | TDP1 682/4885L3MBTL1 656/4885CES1 2100/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | TDP1 134/4885L3MBTL1 243/4885CES1 1111/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | TDP1 4121/4885L3MBTL1 4872/4885CES1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.